- Home
- AARD vs DBI Comparison
AARD vs DBI Comparison
Compare AARD & DBI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- AARD
- DBI
- Stock Information
- Founded
- AARD 2017
- DBI 1991
- Country
- AARD United States
- DBI United States
- Employees
- AARD N/A
- DBI N/A
- Industry
- AARD Biotechnology: Pharmaceutical Preparations
- DBI Clothing/Shoe/Accessory Stores
- Sector
- AARD Health Care
- DBI Consumer Discretionary
- Exchange
- AARD Nasdaq
- DBI Nasdaq
- Market Cap
- AARD 216.6M
- DBI 222.4M
- IPO Year
- AARD 2025
- DBI 1991
- Fundamental
- Price
- AARD $7.74
- DBI $3.56
- Analyst Decision
- AARD Strong Buy
- DBI Hold
- Analyst Count
- AARD 4
- DBI 2
- Target Price
- AARD $31.50
- DBI $4.75
- AVG Volume (30 Days)
- AARD 113.5K
- DBI 1.7M
- Earning Date
- AARD 01-01-0001
- DBI 03-20-2025
- Dividend Yield
- AARD N/A
- DBI 5.62%
- EPS Growth
- AARD N/A
- DBI N/A
- EPS
- AARD N/A
- DBI N/A
- Revenue
- AARD N/A
- DBI $3,009,262,000.00
- Revenue This Year
- AARD N/A
- DBI $3.51
- Revenue Next Year
- AARD N/A
- DBI $2.60
- P/E Ratio
- AARD N/A
- DBI N/A
- Revenue Growth
- AARD N/A
- DBI N/A
- 52 Week Low
- AARD $7.74
- DBI $3.20
- 52 Week High
- AARD $19.58
- DBI $11.06
- Technical
- Relative Strength Index (RSI)
- AARD N/A
- DBI 39.28
- Support Level
- AARD N/A
- DBI $3.71
- Resistance Level
- AARD N/A
- DBI $4.42
- Average True Range (ATR)
- AARD 0.00
- DBI 0.34
- MACD
- AARD 0.00
- DBI 0.05
- Stochastic Oscillator
- AARD 0.00
- DBI 29.51
About AARD Aardvark Therapeutics Inc. Common Stock
Aardvark Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing novel, small-molecule therapeutics to activate innate homeostatic pathways for the treatment of metabolic diseases. It is focused on on developing selective compounds, targeting Bitter Taste Receptors (TAS2Rs) for hunger-associated conditions. Its product candidate, ARD-101, is an oral gut-restricted small-molecule agonist of certain TAS2Rs expressed in the gut lumen for which have initiated a Phase 3 clinical trial for hyperphagia associated with PWS.
About DBI Designer Brands Inc.
Designer Brands Inc is a designer, producer, and retailer of footwear and accessories. The company operates in three reportable segments: the U.S. Retail segment, the Canada Retail segment, and the Brand Portfolio segment. The U.S. Retail segment operates the DSW Designer Shoe Warehouse banner through its direct-to-consumer U.S. stores and e-commerce site. The Canada Retail segment operates The Shoe Company and DSW banners through its direct-to-consumer Canada stores and e-commerce sites. The Brand Portfolio segment earns revenue from the sale of wholesale products to retailers, commissions for serving retailers as the design and buying agent for products under private labels, and the sale of branded products through its direct-to-consumer e-commerce sites.